Clinical trial · Observational
DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB
DETERMINATION OF THE CELL OF ORIGIN (COO) IN PATIENTS DIAGNOSED WITH DIFFUSE LARGE CELL B LYMPHOMA (LDCGB) IN SPANISH HOSPITALS OF GELTAMO GROUP
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low recruitment
Summary
Brief summary (as posted)
This is a prospective, multicenter study, without any therapeutic intervention that will consist of the analysis of the results of the determination of the COO of all the patients diagnosed with LDCGB in the Spanish hospitals of GELTAMO that adhere to the project. The determination of the COO will be carried out prospectively at the Genomic Unit of the Hospital Clínic de Barcelona (IDIBAPS), where the histological samples of the patients will be sent for this purpose. The main study variable will be the description of the COO (germ-center origin \[GCB\], activated \[ABC\], NOT DETERMINABLE, NOT VALUABLE)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CCO | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CCO | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Develop Patform
- timeFrame
- 2 years
- description
- The objective of the study is to develop a platform for the determination of the COO at a national level by means of NanoString in patients diagnosed with LDCGB and to analyze the distribution of this COO.
Secondary outcomes (2)
- measure
- Integration CCO
- timeFrame
- 2 years
- description
- To analyze the feasibility of integrating prospective COO determination into clinical care practice.
- measure
- Determination CCO
- timeFrame
- 15 days
- description
- To determine the distribution of the COO (GCB, ABC or indeterminate) in the cases included in the LDCGB platform of the Spanish sites.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with LDCGB in the Spanish GELTAMO sites, without previous treatment and who decide to join the program. * Age over or equal to 18 years old. * Having voluntarily given informed consent for the sending and processing of biological samples, as well as for the analysis and reporting of the LDCGB COO results Exclusion Criteria: * Absence of histological material available to review histology and determine COO * Patients with LDCGB from any other low-grade lymphoma
References
Publications (0)
Data not yet available